Aptevo Therapeutics Price to Sales Ratio 2014-2021 | APVO

Historical PS ratio values for Aptevo Therapeutics (APVO) over the last 10 years. The current P/S ratio for Aptevo Therapeutics as of January 19, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Aptevo Therapeutics P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-01-20 6.30 2.46
2021-09-30 15.44 $2.57 6.02
2021-06-30 22.43 $2.39 9.40
2021-03-31 30.52 $1.85 16.53
2020-12-31 36.65 $1.30 28.22
2020-09-30 7.60 $0.60 12.69
2020-06-30 8.35 $0.15 57.07
2020-03-31 3.70 0 0.00
2019-12-31 9.16 0 0.00
2019-09-30 8.24 $3.95 2.09
2019-06-30 12.41 $7.55 1.64
2019-03-31 12.60 $11.78 1.07
2018-12-31 17.78 $14.37 1.24
2018-09-30 71.12 $12.27 5.80
2018-06-30 69.86 $12.66 5.52
2018-03-31 45.78 $10.75 4.26
2017-12-31 59.36 $9.61 6.18
2017-09-30 32.06 $0.08 395.06
2017-06-30 28.98 $-1.96 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.032B $0.004B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.655B 9.08
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.351B 19.22
Biohaven Pharmaceutical Holding (BHVN) United States $7.535B 0.00
Emergent Biosolutions (EBS) United States $2.453B 8.82
Arcus Biosciences (RCUS) United States $2.353B 0.00
Myovant Sciences (MYOV) United Kingdom $1.344B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.156B 0.00
Zymeworks (ZYME) Canada $0.627B 0.00
Ambrx Biopharma (AMAM) United States $0.207B 0.00
SQZ Biotechnologies (SQZ) United States $0.207B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81